Day 1 – Tuesday, March 12
8:30-8:55a.m. Welcome Remarks by the Alzheimer’s Association and Perspective from an Advocate - Frank Stephens

8:55-9:10a.m. NIH Perspective
Anna Mazzucco (NIH Office of the Director)

9:10-9:45a.m. Keynote: Intersection of Alzheimer’s & Down Syndrome: What We Know Today
Michael Rafii (University of Southern California)

Session 1: Epidemiology and Factors Impacting Risk for Alzheimer’s in Down Syndrome
Session Chair & Moderator: Joaquin Espinosa (UC Denver)

9:45-10:05a.m. Contributions of Comorbid Conditions to Risk for AD in DS
Andre Strydom (King’s College London)

10:05-10:25a.m. Lifestyle Factors and Risk for AD in DS
Sigan Hartley (University of Wisconsin, Madison)

10:25-10:45a.m. Impact of Sleep on Cognition and AD in DS
Fabian Fernandez (University of Arizona)

10:45-11:10a.m. BREAK

11:10-11:30a.m. Sex Differences in AD Risk in People with DS
Florence Lai (Harvard University)

11:30-11:50a.m. Genetic Risk & Resilience Factors for AD in DS
Joseph H. Lee (Columbia University)

11:50-12:15p.m. Moderated Panel Discussion (Session 1 Speakers, including Eric Doran)

12:15-1:30p.m. LUNCH
**Session 2: AD Imaging Biomarkers in Down Syndrome**
*Session Chair & Moderator:* Juan Fortea (Hospital of Sant Pau; Catalan Down Syndrome Foundation)

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30-1:50 p.m.</td>
<td>Amyloid PET Imaging</td>
<td>Patrick Lao (Columbia University)</td>
</tr>
<tr>
<td>1:50-2:10 p.m.</td>
<td>Tau PET Imaging</td>
<td>Bradley Christian (University of Wisconsin)</td>
</tr>
<tr>
<td>2:10-2:30 p.m.</td>
<td>FDG PET Imaging</td>
<td>Ben Handen (University of Pittsburgh)</td>
</tr>
<tr>
<td>2:30-2:50 p.m.</td>
<td>MRI Imaging of AD in DS</td>
<td>Adam Brickman (Columbia University)</td>
</tr>
<tr>
<td>2:50-3:10 p.m.</td>
<td>DTI Imaging of AD in DS</td>
<td>Diana Rosas (Harvard University)</td>
</tr>
<tr>
<td>3:10-3:35 p.m.</td>
<td>Moderated Panel Discussion (Session 2 Speakers)</td>
<td></td>
</tr>
</tbody>
</table>

**3:35-4:00 p.m. BREAK**

**Session 3: AD Non-Imaging Biomarkers in Down Syndrome**
*Session Chair & Moderator:* James Hendrix (LuMind)

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:00-4:20 p.m.</td>
<td>Fluid Biomarkers of AD in DS</td>
<td>Juan Fortea (Hospital of Sant Pau and Catalan Down Syndrome Foundation)</td>
</tr>
<tr>
<td>4:20-4:40 p.m.</td>
<td>Endophenotyping of AD in DS</td>
<td>Sid O’Bryant (UNT Health Sciences Center)</td>
</tr>
<tr>
<td>4:40-5:00 p.m.</td>
<td>Exosome Based Biomarkers of AD in DS</td>
<td>Ann-Charlotte (Lotta) Granholm (University of Denver / Karolinska Institutet)</td>
</tr>
<tr>
<td>5:00-5:20 p.m.</td>
<td>Moderated Panel Discussion (Session 3 Speakers and Cynthia Lemere)</td>
<td></td>
</tr>
<tr>
<td>5:20-5:30 p.m.</td>
<td>Close of Day One</td>
<td>Michelle Whitten, Representative from Global Down Syndrome Foundation</td>
</tr>
<tr>
<td>5:30-7:00 p.m.</td>
<td>Reception For All Attendees</td>
<td></td>
</tr>
</tbody>
</table>

**DAY 2: Wednesday, March 13, 2019**

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30-8:45 a.m.</td>
<td>Overview of Day One</td>
<td>James Hendrix, Representative from LuMIND Foundation</td>
</tr>
</tbody>
</table>

DS-AD Workshop
**Session 4: Biological Underpinnings of Down Syndrome & Alzheimer’s**  
**Session Chair & Moderator:** Cynthia Lemere (BWH/ Harvard University)

8:45-9:00 a.m. **Interplay of Amyloidosis and Immune Dysregulation in Alzheimer’s and Down Syndrome**  
Joaquin Espinosa (UC Denver)

9:00-9:15 a.m. **Dendritic Spines in DS**  
Jorge Busciglio (University of California, Irvine)

9:15-9:30 a.m. **Cerebrovascular Pathology in DS with AD**  
Elizabeth Head (University of California, Irvine)

9:30-9:45 a.m. **Mosaic Aneuploidy and Cell Cycle Defects in AD and DS**  
Huntington Potter (University of Colorado Denver)

9:45-10:00 a.m. **Tau and Amyloid in Down syndrome with and without Dementia**  
Elliott Mufson (Barrow Neurological Institute)

10:00-10:30 a.m. **Moderated Panel Discussion** (Session 4 Speakers)

10:30-11:00 a.m. **BREAK & CHECKOUT**

**Session 5: Practical Considerations for Clinical Trials**  
**Session Chair & Moderator:** Sid O’Bryant (UNT Health Sciences Center)

11:00-11:20 a.m. **Animal Models for DS and AD to Inform Trial Decisions**  
William Mobley (University of California, San Diego)

11:20-11:40 a.m. **Inclusion/Exclusion Criteria Considerations**  
Priya Kishnani (Duke University)

11:40-12:00 p.m. **Identifying MCI in Down syndrome for Clinical Trials**  
Wayne Silverman (University of California, Irvine)

12:00-12:20 p.m. **Outcome Measures for Clinical Trials in DS**  
Anna Esbensen (University of Cincinnati)

12:20-12:45 p.m. **Moderated Panel Discussion** (Session 5 Speakers & Andre Strydom)

12:45-1:45 p.m. **Lunch**

**Session 6: Clinical Interventions - Landscape of AD trials in DS**  
**Session Chair & Moderator:** Michael Rafii (USC)

1:45-2:05 p.m. **Pipeline of Clinical Interventions for AD in DS**  
Elizabeth Head (UCI)

2:05-2:25 p.m. **Perspective of NIH on AD studies in DS**  
Laurie Ryan (NIA at NIH)

DS-AD Workshop
2:25-2:45p.m. Current and Recent AD trials in DS: Landscape of Pharmacological Studies
   Shahid Zaman (Cambridge University)

2:45-3:05p.m. Pharma Perspective on AD studies in DS
   Bjorn Sperling (Lundbeck)

3:05-3:30p.m. Moderated Panel Discussion (Session 6 Speakers)

Next Steps & Future Initiatives
3:30-4:00p.m. Next Steps, Future Initiatives & Closing Remarks
   Moderated by: Michael Rafii, Laurie Ryan, and Heather Snyder

4:00p.m. Departures